Neovasc to Participate in the 28th Annual Credit Suisse Healthcare Conference on Wednesday, November 13, 2019

VANCOUVER, Oct. 30, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE —Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQTSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that Fred Colen, CEO of Neovasc, will be participating in the 28th annual Credit Suisse Healthcare Conference in Scottsdale, AZ.   Mr. Colen’s presentation will take place at 10:00 a.m. EST (8:00 a.m. MT).  
A live audio webcast of the Credit Suisse Conference presentation will be available online from the investor relations section of the Neovasc website at https://www.neovasc.com/investors/ or through the following link https://cc.talkpoint.com/cred001/111219a_js/?entity=26_YQEL8W0.About Neovasc Inc.Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include Reducer, for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and Tiara, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. For more information, visit: www.neovasc.com.InvestorsMike CavanaughWestwicke/ICRPhone: +1.646.877.9641[email protected]MediaSean LeousWestwicke/ICRPhone: +1.646.677.1839[email protected]Forward-Looking Statement DisclaimerCertain statements in this news release contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws that may not be based on historical fact.  When used herein, the words “expect”, “anticipate”, “estimate”, “may”, “will”, “should”, “intend,” “believe”, and similar expressions, are intended to identify forward-looking statements. Forward-looking statements may involve, but are not limited to, expectations as to the future growth of the Company, the expansion of its product range and the growing cardiovascular marketplace. Forward-looking statements are based on estimates and assumptions made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Company believes are appropriate in the circumstances.  Many factors could cause the Company’s actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including those described in the “Risk Factors” section of the Company’s Annual Report on Form 20-F and in the Management’s Discussion and Analysis for the three and six months ended June 30, 2019 (copies of which may be obtained at www.sedar.comor www.sec.gov).  These factors should be considered carefully, and readers should not place undue reliance on the Company’s forward-looking statements. The Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Bay Street News

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt

Start typing and press Enter to search